Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.22B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 2.82M
Average 2.55M
EXEL EBITDA Margin
EBITDA as a percentage of revenue.
Exelixis, Inc.NASDAQ: EXEL
EBITDA Margin · Q2 FY2026 · quarter ended Jul 2026
EBITDA Margin widens to 42.9%
EBITDA Margin was 42.9% in Q2 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 43.0%, up 6.3 pp year over year. Over 3 fiscal years it widened by 23.9 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 53.3% for the fiscal year ending Jan 2027, up from 39.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- 42.9%-2.1 pp QoQ
- Last fiscal yearJan 2026
- 39.7%+6.6 pp YoY
- LTMJul 2026
- 43.0%+6.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.1 pp | +1.8 pp | +0.8 pp |
| 1 year | +6.6 pp | +13.5 pp | +7.0 pp |
| 3 years | +23.9 pp | +11.1 pp | -12.8 pp |
| 5 years | +24.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 39.7%
- Year-over-year change
- +6.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 39.7% | +6.6pp |
| FY2024 | 2025-01-03 | 33.1% | +17.7pp |
| FY2023 | 2023-12-31 | 15.5% | -0.4pp |
| FY2022 | 2022-12-31 | 15.8% | -5.6pp |
| FY2021 | 2021-12-31 | 21.4% | — |
EBITDA Margin vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 EBITDA Margin of 43.0% is the 2nd highest of the 7 companies compared; the peer median is 31.9%.
- Its year-over-year change of +6.3 pp is the 4th highest of 6, against a peer median of +16.8 pp.
- Over three fiscal years its change of +23.9 pp compares with a peer median of +16.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Jul 2026 | 43.0% | +6.3 pp | +23.9 pp | |
| LTM Jun 2026 | 35.5% | +6.0 pp | +16.6 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Jun 2026 | 29.5% | — | -14.7 pp | |
| LTM Jun 2025 | -1.2% | +16.8 pp | +86.5 pp | |
| LTM Mar 2026 | -74.8% | +669.1 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding EXEL) | 31.9% | +16.8 pp | +16.6 pp | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Cost of Revenue | 52.87M | 57.91M | 72.55M | 76.22M | 83.7M |
| Gross Profit | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B |
| Gross Margin | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Research & Development | 693.72M | 891.81M | 1.04B | 910.41M | 825M |
| Selling, General & Admin | 401.72M | 459.86M | 542.71M | 492.13M | 518.73M |
| Operating Expenses | 1.1B | 1.35B | 1.59B | 1.49B | 1.36B |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| EBITDA | 307.78M | 255.23M | 283.24M | 718.75M | 921.76M |
| EBITDA Margin | 21.4% | 15.8% | 15.5% | 33.1% | 39.7% |
| Operating Income | 286.67M | 201.48M | 170.89M | 604.62M | 872.19M |
| Operating Margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Interest Income | 7.67M | 33.07M | 86.54M | 77.16M | 69.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.49M | 32.87M | 86.64M | 77.02M | 69.02M |
| Income Before Tax | 294.15M | 234.35M | 257.52M | 681.64M | 941.21M |
| Pre-Tax Margin | 20.5% | 14.5% | 14.1% | 31.4% | 40.6% |
| Income Tax Expense | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M |
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Net Margin | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| EPS (Basic) | 0.73 | 0.57 | 0.65 | 1.80 | 2.88 |
| EPS (Diluted) | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| Weighted Avg Shares | 314.88M | 321.53M | 318.15M | 290.03M | 271.57M |
| Weighted Avg Shares (Diluted) | 322.36M | 324.56M | 321.46M | 296.13M | 281.86M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.